Viewing Study NCT03950258


Ignite Creation Date: 2025-12-25 @ 12:07 AM
Ignite Modification Date: 2025-12-25 @ 10:06 PM
Study NCT ID: NCT03950258
Status: COMPLETED
Last Update Posted: 2020-05-13
First Post: 2019-05-13
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Endovascular Management of Pediatric Intracranial Arteriovenous Shunts
Sponsor: Assiut University
Organization:

Study Overview

Official Title: Endovascular Management of Pediatric Intracranial Arteriovenous Shunts
Status: COMPLETED
Status Verified Date: 2020-05
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: * Review the outcomes of the Endovascular management of pediatric intracranial arteriovenous shunts.
* Give an effective treatment for pediatric intracranial arteriovenous shunts and can detect the best method could be used and assess safety and efficacy of different endovascular techniques in treatment of different AV shunts.
* Improve the outcome of these patients and decease rate of recurrence and complications.
Detailed Description: Intracranial arteriovenous shunts (ICAVS) in young children are characterized by frequent high-flow fistulas. In association with high-flow fistulas and the physiological condition of the developing brain and heart, each ICAVS type tends to present at a certain age with unique symptoms.

Vein of Galen aneurysmal malformation (VGAM) and dural sinus malformation with arteriovenous (AV) shunt tend to present in the neonate with high output cardiac failure. In infancy, VGAM, pial arteriovenous fistula (AVF) and infantile dural AVF (DAVF) tend to present with hydrodynamic disorder such as macrocephaly, ventriculomegaly, prominent facial veins, and developmental delay.

Pial AVF, AV malformation, and infantile DAVF can present with focal neurological signs such as seizure or hemorrhage at older ages they are in the subpial space, as opposed to VGAM or DAVF, which are extrapial in location and tend to present with systemic symptoms .

Endovascular treatment is currently the first choice of treatment for most pediatric ICAVS. The treatment goal should be defined on a patient-by-patient basis, according to the unique physiological condition of the child.

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: